Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 2 |
| Emerging Market for Clinical Trials - India - Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Emerging Market for Clinical Trials - India - Overview | 10 | 17 |
| The Clinical Research Process Overview | 10 | 1 |
| Drug Discovery Phase | 10 | 1 |
| Pre-Clinical Phase | 10 | 1 |
| Phase I | 11 | 1 |
| Phase II | 11 | 1 |
| Phase III | 11 | 1 |
| Review and Approval from the Regulatory Agencies | 11 | 1 |
| Post-marketing Studies | 11 | 1 |
| Clinical Trial Design and Types | 11 | 1 |
| Types of Design | 12 | 1 |
| Parallel Group Trial Design | 12 | 1 |
| Cross over Trial Design | 13 | 1 |
| Adaptive Clinical Trial Design | 14 | 2 |
| Wyeth s Learn &Confirm Model | 16 | 2 |
| Role of CROs | 18 | 1 |
| Sponsors of Clinical Trials | 19 | 1 |
| Intellectual Property Protection in India | 20 | 1 |
| Patent Act 2005 First Step towards Improving IP Protection | 20 | 1 |
| Intellectual Property Rights (IPR) Enforcement Rules, 2007 | 20 | 1 |
| Trademarks Bill 2007 | 21 | 1 |
| Drugs and Cosmetics Act (Amendment) 2008 | 21 | 1 |
| Enforcers of Intellectual Property Rights (EIPR) Ensuring IPR Laws Implementation in India | 21 | 1 |
| The Need for Outsourcing Clinical Trials | 22 | 1 |
| High Risks and Costs Associated With Drug Development | 22 | 1 |
| Escalating Costs of Clinical Trials | 23 | 1 |
| Global Increase in the Number of Clinical Trials Conducted | 24 | 1 |
| Restructuring the R&D | 25 | 1 |
| Increased Screening Rates During R&D | 26 | 1 |
| Expiring Patents Pressurize Pharmaceutical Companies to Reduce Costs | 26 | 1 |
| Emerging Market for Clinical Trials India - Clinical Trial Trends | 27 | 15 |
| Registration of Phase l Clinical Trials | 27 | 1 |
| Registration of Phase ll Clinical Trials | 28 | 1 |
| Registration of Phase lll Clinical Trials | 29 | 1 |
| Registration of Phase lV Clinical Trials | 30 | 1 |
| Clinical Trials Registered in 2009 | 31 | 1 |
| Comparative Analysis of Registered Clinical Trials in BRIC Countries | 32 | 1 |
| Comparative Analysis of Industry Sponsored Clinical Trials Started in BRIC Countries | 33 | 1 |
| Comparative Analysis of Population Statistics in BRIC Countries | 34 | 1 |
| Comparative Analysis of Epidemiology and Prevalence of Major Disease | 35 | 1 |
| Number of Recruiting Sites for Major Therapeutics in India, Brazil and China | 35 | 2 |
| Number of Recruiting Sites by Multinational Companies (MNCs) in India, Brazil and China | 37 | 2 |
| Industry Sponsored Trials Registered with the US Trial Register | 39 | 1 |
| Local and Multinational Sites Registered With the US Trial Register | 40 | 1 |
| Number of Sites Involved in Planning, Recruiting, Ongoing and Completed Clinical Trials in India, Brazil and China | 41 | 1 |
| Emerging Market for Clinical Trials India - Market Environment Characterization | 42 | 21 |
| Increase in Growth of Global CRO Market will Foster the Growth of Indian Clinical Trial Market | 42 | 1 |
| Increase in Multinational Sites to Conduct Clinical Trials will Drive the Clinical Trial Market in India | 43 | 1 |
| Access to a Large Patient Pool | 44 | 2 |
| Patient Availability for Major Diseases | 46 | 1 |
| Comparative Analysis of Different Countries for DALY Rate per 1000 Population | 46 | 1 |
| HIV/AIDS | 47 | 1 |
| Cardiovascular Diseases | 48 | 1 |
| Diabetes | 49 | 1 |
| Cancer | 50 | 1 |
| Chronic Obstructive Pulmonary Disease (COPD) and Asthma | 51 | 1 |
| Ethnicity and Genetic Diversity | 52 | 1 |
| Subject Recruitment and Speed of Trials | 52 | 1 |
| Cost of Conducting Clinical Trials in India is Approximately 55% of the Cost of Conducting a Clinical Trial in the US | 52 | 1 |
| Infrastructural Facilities Improve the Clinical Trial Environment | 53 | 1 |
| Hospitals | 53 | 1 |
| Facilities for Conducting Clinical Trials | 54 | 1 |
| Biotechnology Laboratories that Conduct Clinical Trials in India | 54 | 1 |
| Central Drug Research Institute (CDRI) | 54 | 1 |
| Institute of Genomics and Integrative Biology (IGIB) | 54 | 1 |
| Centre for Cellular and Molecular Biology (CCMB) | 54 | 1 |
| Indian Institute of Chemical Biology (IICB) | 55 | 1 |
| GLP Approved Facilities in India | 55 | 1 |
| US FDA Approved New Drug Molecules Being Researched in India | 56 | 1 |
| Increase in Skilled Pool of Healthcare Professionals | 57 | 1 |
| Doctors Registered with State Medical Councils | 57 | 1 |
| Dental Surgeons Registered with State Dental Councils of India | 58 | 1 |
| Increase in Principal Investigators | 59 | 1 |
| Market Restraints | 60 | 1 |
| Lack of Training for Clinical Trial Professionals | 60 | 1 |
| Quality of Clinical Trial Data | 60 | 1 |
| ICH GCP Versus Indian GCP | 60 | 1 |
| Article 39.3 of TRIPS | 61 | 1 |
| Ethical Issues | 61 | 1 |
| Illegal and unethical Clinical Trials | 61 | 1 |
| Slow Hiring in the Government Regulatory Bodies | 61 | 1 |
| The Need for Proposed Additional Documents for Importing Drugs | 61 | 1 |
| Clinical Trial Market Size in India | 62 | 1 |
| Emerging Market for Clinical Trials India - Regulatory Landscape | 63 | 12 |
| Introduction | 63 | 1 |
| Drugs and Cosmetics Act | 63 | 1 |
| The Institutional Ethics Committee (IEC) | 64 | 1 |
| The Ministry of Health and Family Welfare | 64 | 1 |
| Central Drug Standard Control Organization (CDSCO) | 64 | 1 |
| Drug Controller General of India (DCGI) | 64 | 1 |
| Indian Council of Medical Research (ICMR) | 65 | 1 |
| Clinical Trials Registry India | 65 | 2 |
| Clinical Trial Regulation in India | 67 | 2 |
| Documents Required for Phase l Clinical Trial Application for Molecules Discovered in India | 69 | 2 |
| Documents Required for Phase l Clinical Trial (Molecules Discovered Outside India) | 71 | 1 |
| Documents Required for Phase ll Clinical Trial Application | 71 | 1 |
| Documents Required for Phase lll Clinical Trials | 72 | 1 |
| Time Frame for Approval | 72 | 1 |
| Recent Regulatory Changes in Clinical Trials | 73 | 1 |
| Amended Schedule Y | 73 | 1 |
| Informed Consent and its Elements | 73 | 1 |
| Investigator Undertaking | 74 | 1 |
| Government Incentives | 74 | 1 |
| Emerging Market for Clinical Trials India - CRO Landscape | 75 | 17 |
| CRO Locations | 75 | 1 |
| Service Portfolio and Benchmarking of Indian CROs | 76 | 1 |
| Acquisitions by Indian CROs | 77 | 1 |
| CRO Profiles | 78 | 1 |
| Reliance Life Sciences | 78 | 1 |
| Business Description | 78 | 1 |
| Asian Clinical Trials | 79 | 1 |
| Business Description | 79 | 1 |
| Diagnosearch Life Sciences | 80 | 1 |
| Business Description | 80 | 1 |
| Clininvent | 81 | 1 |
| Business Description | 81 | 1 |
| Synchron Research Services Pvt Ltd | 82 | 1 |
| Business Description | 82 | 1 |
| Lambda Therapeutic Research Ltd | 83 | 1 |
| Business Description | 83 | 1 |
| GVK Biosciences Pvt Ltd | 84 | 1 |
| Business Description | 84 | 1 |
| Sristek | 85 | 1 |
| Business Description | 85 | 1 |
| Lotus Laboratories Pvt Ltd | 86 | 1 |
| Business Description | 86 | 1 |
| Veeda Clinical Research Ltd | 87 | 1 |
| Business Description | 87 | 1 |
| Vimta Labs Ltd | 88 | 1 |
| Business Description | 88 | 1 |
| Ecron Acunova | 89 | 1 |
| Business Description | 89 | 1 |
| SIRO Clinpharm Pvt Ltd | 90 | 1 |
| Business Description | 90 | 1 |
| Catalyst Clinical Services | 91 | 1 |
| Business Description | 91 | 1 |
| Emerging Market for Clinical Trials India - Appendix | 92 | 5 |
| Market Definitions | 92 | 1 |
| Abbreviations | 92 | 2 |
| Research Methodology | 94 | 2 |
| Coverage | 94 | 1 |
| Secondary Research | 94 | 1 |
| Primary Research | 94 | 1 |
| Expert Panel Validation | 95 | 1 |
| Contact Us | 95 | 1 |
| Disclaimer | 95 | 1 |
| Sources | 96 | 1 |